Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.86 |
| ▸ | HEXA | P06865 | 15/20 | 0.78 |
| ▸ | HEXB | P07686 | 15/20 | 0.78 |
| ▸ | OGA | O60502 | 1/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292141 | 0.97 | SIRT1 (0.81) | SIRT1HEXAHEXBOGALCK | |
| Elinafide SCHEMBL19067 | 0.93 | SIRT1 (1.00) | SIRT1HEXAHEXBOGA | |
| Elinafide SCHEMBL29441732 | 0.93 | SIRT1 (1.00) | SIRT1HEXAHEXBOGA | |
| Elinafide SCHEMBL6256967 | 0.93 | SIRT1 (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL9092483 | 0.92 | HEXA (0.82) | SIRT1HEXAHEXBOGALCK | |
| Hydrochloric Acid SCHEMBL5748029 | 0.92 | HEXA (0.82) | SIRT1HEXAHEXBOGALCK | |
| SCHEMBL8396162 | 0.90 | SIRT1 (0.94) | SIRT1HEXAHEXBOGA | |
| SCHEMBL4408773 | 0.88 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL31011151 | 0.88 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL25868576 | 0.87 | SIRT1 (0.79) | SIRT1HEXAHEXBOGALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2010-12-30 | — | — | US | disclosed |
| US-7728000-B2 | Substituted quinolines for the treatment of cancer | CRYSTAX PHARMACEUTICALS (ES) | 2010-06-01 | — | — | US | disclosed |
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-05-10 | — | — | US | disclosed |
| EP-1687304-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | Crystax Pharmaceuticals S.L. (ES) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054236-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS S.L. (ES) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | TOP2B, NQO2, SNRPD2 | SIRT1 504/4885HEXA 1139/4885HEXB 953/4885 |
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | TOP2B, TOP1, TOP2A | SIRT1 314/4885HEXA 1337/4885HEXB 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.